Aditxt Inc. (NASDAQ: ADTX) shares fell 25.86% to $1.60, hitting a 52-week low. This decline comes despite broader market strength, with the Nasdaq-100 up 1.81% and the S&P 500 up 1.15%.
The stock's significant drop is attributed to a sector rotation, as investors reacted to the company's recent announcement of a special stockholder meeting scheduled for January 30, 2026, which includes proposals for a potential reverse stock split and a name change to 'bitXbio, Inc.' Despite the recent surge in after-hours trading, ADTX has experienced a staggering 99.97% decline year-to-date.
This movement reflects the ongoing volatility in the biotech sector, where investor sentiment can shift rapidly based on corporate announcements and market conditions. The upcoming shareholder meeting may provide clarity on the company's future direction, but the current price action indicates a cautious approach from investors.
Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
